Literature DB >> 19261683

Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer.

Sonia Cheng1, Wei Liu, Moises Mercado, Shereen Ezzat, Sylvia L Asa.   

Abstract

Thyroid cancer exhibits a spectrum from relatively indolent tumors to tumors that are invasive, metastatic, or progress to poorly differentiated carcinoma. Microarray expression analysis of thyroid cancer cell lines has implicated a member of the melanoma-associated (MAGE) family of cancer-testis antigens in thyroid cancer development and progression. We performed this study to validate the role of MAGE in human thyroid cancers. A tissue microarray (TMA) of samples from 375 patients with thyroid cancer was analyzed with immunohistochemistry (IHC) to localize MAGE. Western blotting of fractionated proteins from MAGE-transfected cells was used to confirm intracellular localization of proteins. Automated analysis of TMA samples was evaluated and subjected to statistical analysis. MAGE immunoreactivity was identified in nuclear and cytoplasmic compartments of normal and malignant tissues. Specificity of staining was proved by fractionation studies that confirmed MAGE expression in nucleus and cytoplasm. Normal thyroid tissue exhibited weak cytoplasmic and strong nuclear MAGE reactivity. Tumors exhibited an increase in cytoplasmic MAGE scores that correlated with clinical behavior: larger tumors had higher MAGE scores, and there was a positive and significant correlation between MAGE cytoplasmic score and the number of histologically proven lymph node metastases. There was a statistically significant negative correlation between cytoplasmic MAGE and the percentage of p53-positive nuclei. Our data confirm gene-profiling evidence that members of the MAGE family play a role in thyroid cancer progression. The use of TMA analyses identifies IHC techniques that are translatable to the clinical setting for prognostic assessment of patients with thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19261683     DOI: 10.1677/ERC-09-0002

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  7 in total

1.  Human MageB2 Protein Expression Enhances E2F Transcriptional Activity, Cell Proliferation, and Resistance to Ribotoxic Stress.

Authors:  Leticia Y Peche; María F Ladelfa; María F Toledo; Miguel Mano; Julieta E Laiseca; Claudio Schneider; Martín Monte
Journal:  J Biol Chem       Date:  2015-10-14       Impact factor: 5.157

Review 2.  Molecular markers of aggressiveness of thyroid cancer.

Authors:  Matthew D Ringel
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-10       Impact factor: 3.243

Review 3.  Immunohistochemical Biomarkers in Thyroid Pathology.

Authors:  Zubair Baloch; Ozgur Mete; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

4.  Advances in cellular therapy for the treatment of thyroid cancer.

Authors:  Claudia Papewalis; Margret Ehlers; Matthias Schott
Journal:  J Oncol       Date:  2010-06-29       Impact factor: 4.375

5.  The insulin resistance Grb14 adaptor protein promotes thyroid cancer ret signaling and progression.

Authors:  K Balogh; S L Asa; L Zheng; C Cassol; S Cheng; S Ezzat
Journal:  Oncogene       Date:  2011-12-12       Impact factor: 9.867

6.  CD8+ TIL recruitment may revert the association of MAGE A3 with aggressive features in thyroid tumors.

Authors:  Mariana Bonjiorno Martins; Marjory Alana Marcello; Fernando de Assis Batista; Lucas Leite Cunha; Elaine Cristina Morari; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  J Immunol Res       Date:  2014-11-04       Impact factor: 4.818

7.  Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases.

Authors:  Daniel Hardy Melo; Rui Celso Martins Mamede; Luciano Neder; Wilson Araújo Silva; Mateus Camargo Barros-Filho; Luiz Paulo Kowalski; Clóvis Antonio Lopes Pinto; Marco Antônio Zago; David Livingstone Alves Figueiredo; Achim A Jungbluth
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.